Search
Search Results
-
Wnt/β-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells
BackgroundTrastuzumab is the only approved target agent for the first-line treatment of human epidermal growth factor receptor-2 (HER-2) positive...
-
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is characterized by invasive growth, rapid metastasis and chemoresistance....
-
Trastuzumab for Active Targeting in Cancer Therapy
With the advent of targeted therapies came a new paradigm for cancer treatment. The specific interaction between ligands and surface receptors has...
-
Exosomal Linc00969 induces trastuzumab resistance in breast cancer by increasing HER-2 protein expression and mRNA stability by binding to HUR
BackgroundBreast cancer (BC) is the most common malignant disease in female patients worldwide. In HER-2+ BC patients, trastuzumab therapy is...
-
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
BackgroundAlthough trastuzumab and other HER2-targeted therapies have significantly improved survival in patients with HER2 overexpressed or...
-
β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features
BackgroundThe emergence of de novo or intrinsic trastuzumab resistance is exceedingly high in breast cancer that is HER2 positive and correlates with...
-
MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy
Although resistance is its major obstacle in cancer therapy, trastuzumab is the most successful agent in treating epidermal growth factor receptor 2...
-
circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer
BackgroundApproximate 25% HER2-positive (HER2 + ) breast cancer (BC) patients treated with trastuzumab recurred rapidly. However, the mechanisms...
-
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
BackgroundTrastuzumab is the only first-line treatment targeted against the human epidermal growth factor receptor 2 (HER2) approved for patients...
-
Establishment of a trastuzumab-resistant extramammary Paget disease model: loss of PTEN as a potential mechanism
Background/objectivesExtramammary Paget disease (EMPD) is a rare, cutaneous intraepithelial adenocarcinoma typically treated with wide local...
-
Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
BackgroundHER2-positive breast cancer occurs in 15–20% of breast cancer patients and is characterized by poor prognosis. Trastuzumab is considered...
-
Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo
BackgroundResistance to HER2-targeted therapies, including the monoclonal antibody trastuzumab and tyrosine kinase inhibitor lapatinib, frequently...
-
Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model
Human epidermal growth factor 2 (HER2)-positive breast cancer with lung metastases resistant to targeted agents is a common therapeutic challenge....
-
Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models
BackgroundPrevious studies have suggested that patients with HER2-low breast cancers do not benefit from trastuzumab treatment although the reasons...
-
Inhibition of PFKFB3 in HER2-positive gastric cancer improves sensitivity to trastuzumab by inducing tumour vessel normalisation
BackgroundMultiple mechanisms have been proposed that lead to reduced effectiveness of trastuzumab in HER2-positive gastric cancer (GC), yet...
-
Circular RNA hsa_circ_0001598 promotes programmed death-ligand-1-mediated immune escape and trastuzumab resistance via sponging miR-1184 in breast cancer cells
Approximately 25% of breast cancer (BC) patients are HER2-positive. Trastuzumab is used as a targeted therapy drug to treat HER2-positive BC...
-
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) patients are at a high risk of develo** metastases in the brain....
-
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial
Trastuzumab deruxtecan (T-DXd) showed statistically significant clinical improvement in patients with human epidermal growth factor receptor...
-
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
BackgroundOverexpression of human epidermal growth factor receptor 2 (HER2) caused by HER2 gene amplification is a driver in breast cancer...
-
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
BackgroundCurrent guidelines recommend that patients with HER2-low metastatic breast cancer (MBC) receive sequentially two antibody–drug conjugates...
